XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Operating Activities              
Net loss $ (9,525,294) $ (4,305,931) $ (214,247) $ (4,929,030) $ (13,831,224) $ (5,143,277)  
Adjustments to reconcile net loss to cash used in operating activities:              
Depreciation, amortization and accretion         4,012,909 2,157,540  
Stock-based compensation expense         962,977 327,435  
Loss from change in fair value of contingent consideration 3,313,656     2,411,333  
(Gain) from derecognition of contingent consideration   (5,199,806)   (5,199,806)  
Loss on sale of equipment         112,110  
(Gain) on termination of lease         (343,185)  
Loss on debt exchange 257,559     257,559  
Changes in allowance for bad debt         147,627  
Loss from change in fair value of CVR         899,987  
Derivative income         (1,830)  
Changes in operating assets and liabilities:              
Increase in accounts receivable         (1,965,271) (3,456,364)  
Increase in inventory         (3,615,662) (132,199)  
Increase in prepaid expenses and other         (379,337) (171,430)  
Decrease (increase) in other current assets         2,295,055 (136,694)  
(Decrease) increase in accounts payable and other         (3,136,163) 2,806,973  
Increase in accrued liabilities         1,711,466 145,467  
Decrease in accrued compensation         (576,824) (62,729)  
Decrease in fixed payment arrangements         (216,150)  
Increase in contract liability         136,344  
Decrease in deferred rent         (3,990)  
Net cash used in operating activities         (10,900,299) (9,087,054)  
Investing Activities              
Deposit         (3,923)  
Contingent consideration payment         (42,760) (104,635)  
Note receivable         (1,350,000)  
Purchase of assets         (4,500,000)  
Net cash used in investing activities         (46,683) (5,954,635)  
Financing Activities              
Issuance of preferred, common stock and warrants         32,249,652 10,000,000  
Issuance cost related to registered offering         (4,292,781) (741,650)  
Payments made to borrowings         (272,727)  
Payments made to fixed payment arrangements         (2,785,863)  
Net cash provided by financing activities         24,898,281 9,258,350  
Net change in cash, restricted cash and cash equivalents         13,951,299 (5,783,339)  
Cash, restricted cash and cash equivalents at beginning of period   $ 48,333,307   $ 11,294,227 48,333,307 11,294,227 $ 11,294,227
Cash, restricted cash and cash equivalents at end of period $ 62,284,606   $ 5,510,888   62,284,606 5,510,888 $ 48,333,307
Supplemental disclosures of cash and non-cash investing and financing transactions              
Warrants issued to underwriters         356,139  
Cash paid for interest         306,752 3,390  
Fair value of right-to-use asset and related lease liability         43,082 412,691  
Contingent consideration included in accounts payable         3,430  
Debt exchange         1,057,559  
Fixed payment arrangements included in accrued liabilities         1,050,000  
Inventory swap         7,043,849  
Acquisition costs included in accounts payable         59,014  
Conversion of Convertible Preferred Stock into Common Stock [Member]              
Supplemental disclosures of cash and non-cash investing and financing transactions              
Exchange of convertible preferred stock into common stock         $ 44